少なくとも1種類の非生物学的疾患修飾性抗リウマチ薬（DMARD）で十分な効果が得られなかった乾癬性関節炎患者を対象に、ウパダシチニブ（ABT-494）とプラセボおよびアダリムマブを比較する試験

基本情報

NCT ID

NCT03104400

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,705

治験依頼者名

AbbVie

概要

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg and 30 mg QD versus placebo for the prevention of structural progression. The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg and 30 mg QD in participants who have completed Period 1.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)